Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure (BENEFIT-HF)

NCT07232030 is registered in ClinicalTrials.gov with CVRx, Inc. as lead sponsor.

NCT NCT07232030
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07232030 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure (BENEFIT-HF)
Lead sponsor
CVRx, Inc.
Phase
Not applicable
Overall status
Recruiting
Start date
April 24, 2026
Completion date
January 31, 2033
Enrollment
2,500 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure, heart failure nyha class ii, heart failure nyha class iii